In parallel, the discovery of immune checkpoint molecules, such as programmed cell death 1 and cytotoxic T-lymphocyte antigen-4, has enabled a new strategy of cancer immunotherapy, and immune checkpoint inhibitors (ICIs) have dramatically improved the prognosis of various cancers. Here, PDCD1 is linked to cancer.